Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: From Brain on Yahoo

RG has stated there will be no dividends and the money will be used for M&A and growing the company beyond the MMP. The current BOD must be with him on this issue.

The Yahoo board BOD bashers need to understand that at Agoracom investors do not want to dwell on the past failures of David Pohl and the old BOD. We're done with this issue the CEO that headed those decisions is gone. We want to move on and focus on the future potential of PTSC with the existing management and BOD members. PTSC has enough quality new managment to get the job done and has been making excellant decisions IMO.

Lets keep the focus on what really matters right now the USPTO reexamination process, the patents, and potential M&A activity.

All the best,

Steve

Share
New Message
Please login to post a reply